SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

14 Aug 2023 Evaluate
A slight decline in the revenue of Rs. 3941.22 millions was seen for the June 2023 quarter as against Rs. 4030.23 millions during year-ago period.Profit after Tax for the quarter ended June 2023 saw a decline of -53.73% from Rs. 39.36 millions to Rs. 18.21  millions.Operating profit for the quarter ended June 2023 decreased to 360.13 millions as compared to 422.09 millions of corresponding quarter ended June 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 3941.22 4030.23 -2.21 3941.22 4030.23 -2.21 15246.09 16682.56 -8.61
Other Income 4.73 3.64 29.95 4.73 3.64 29.95 422.39 112.93 274.03
PBIDT 360.13 422.09 -14.68 360.13 422.09 -14.68 979.02 1701.31 -42.45
Interest 176.22 213.66 -17.52 176.22 213.66 -17.52 794.77 788.10 0.85
PBDT 183.91 208.43 -11.76 183.91 208.43 -11.76 184.25 913.21 -79.82
Depreciation 153.32 146.95 4.33 153.32 146.95 4.33 591.19 569.68 3.78
PBT 30.59 61.48 -50.24 30.59 61.48 -50.24 -406.94 343.53 -218.46
TAX 12.38 22.12 -44.03 12.38 22.12 -44.03 -182.37 90.34 -301.87
Deferred Tax 12.38 22.12 -44.03 12.38 22.12 -44.03 -182.37 90.34 -301.87
PAT 18.21 39.36 -53.73 18.21 39.36 -53.73 -224.57 253.19 -188.70
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 7.99 9.06 -11.87 9.14 10.47 -12.75 5.60 8.84 -36.61

Nectar Lifesciences Share Price

12.26 0.32 (2.68%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×